HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Many European Nations Not Advocating Supplement Use During COVID Pandemic

Executive Summary

Analysis of 12 European countries shows most governments are not promoting the use of dietary supplements to support immunity during the COVID-19 pandemic.

You may also be interested in...



UK’s National Health Service Recommends Daily Vitamin D Supplementation

The UK's National Health Service recommends 10μg a day of vitamin D for those unable to get enough sunlight due to self-isolation, and also warns against taking supplements for COVID-19. 

France Warns Supplements Can Interfere With Immune Response To COVID-19

Dietary supplements containing certain plants can inhibit the immune response to COVID-19 and should not be taken by those showing symptoms of the virus, according to French regulator ANSES.

Taisho Boosted By Acquisitions As Japanese Business Struggles

Acquiring France's UPSA helped to lift Taisho's sales in the 12 months ended 31 March 2020, as its domestic Japanese business faltered.

Topics

UsernamePublicRestriction

Register

SC018508

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel